Treatment intensification in patients with inadequate glycemic control on basal insulin: Rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists
Treatment intensification in patients with inadequate glycemic control on basal insulin: Rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists
(2016)
Authors:
Giorgino, Francesco; Bonadonna, Riccardo; Gentile, Sandro; Vettor, Roberto; Pozzilli, Paolo
Title:
Treatment intensification in patients with inadequate glycemic control on basal insulin: Rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists
Year:
2016
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
Diabetes Metabolism Research and Reviews
ISSN of journal:
1520-7552
N° Volume:
32
Number or Folder:
6
Page numbers:
497-511
Keyword:
Algorithms; Exenatide; GLP-1 receptor agonist; Intensification; Latent autoimmune diabetes in adults (LADA); Lixisenatide; Endocrinology; Endocrinology; Diabetes and Metabolism; Internal Medicine
Short description of contents:
A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed.
Giorgino, Francesco; Bonadonna, Riccardo; Gentile, Sandro; Vettor, Roberto; Pozzilli, Paolo,
Treatment intensification in patients with inadequate glycemic control on basal insulin: Rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists«Diabetes Metabolism Research and Reviews»
, vol. 32
, n. 6
, 2016
, pp. 497-511